Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIVe regimen in previously untreated TP53-aberrant chronic lymphocytic leukemia
2015-004606-41Phase 2Completed
- Sponsor
- University Hospital Ulm
- Start
- Apr 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University Hospital Ulm. Primary endpoint: Complete response rate. Started Apr 2016; status: completed.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-004606-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004606-41.